If it were on late-night cable, FDA’s expert panel meeting on attention deficit/hyperactivity disorder drugs might be called "Advisory Committees Gone Wild."
FDA convened its Drug Safety & Risk Management Advisory Committee on February 9 to discuss ways to study a potential...






